TherapeuticsMD
TXMD
159 hedge funds and large institutions have $197M invested in TherapeuticsMD in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 12 closing their positions.
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
12% more funds holding
Funds holding: 142 → 159 (+17)
0.08% less ownership
Funds ownership: 1.17% → 1.09% (-0.08%)
8% less call options, than puts
Call options by funds: $1.17M | Put options by funds: $1.27M
22% less capital invested
Capital invested by funds: $252M → $197M (-$54.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.7M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$4.52M |
| 4 |
BlackRock
New York
|
+$3.72M |
| 5 |
Axa
Paris,
France
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$17.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$12.9M |
| 3 |
IM
Islet Management
New York
|
-$2.37M |
| 4 |
Goldman Sachs
New York
|
-$1.28M |
| 5 |
CC
Clearline Capital
New York
|
-$1.15M |
TXMD Hedge Fund Activity: Q4 2020 in Review
159 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2020, worth a combined $197M — down 22% from $252M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new TXMD positions and 12 closed out — a net gain of 17 holders — while 45 added to existing stakes and 39 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12.5M. The largest seller was JP Morgan Chase, cutting an estimated $17.1M.
- 159 institutional investors held TherapeuticsMD (TXMD) as of Q4 2020, up from 142 in Q3 2020.
- Funds reported $197M of TherapeuticsMD stock for Q4 2020, down 22% quarter-over-quarter.
- 29 funds opened new TherapeuticsMD positions in Q4 2020 and 12 closed out, a net change of +17 holders.
- The largest TherapeuticsMD buyer in Q4 2020 was Morgan Stanley, an estimated $12.5M added.
- The largest TherapeuticsMD seller in Q4 2020 was JP Morgan Chase, an estimated $17.1M sold.
Based on aggregated 13F filings for Q4 2020.